The specificity of serpin superfamily protease inhibitors such as a1-antitrypsin or Ci inhibitor is determined by the amino acid residues of the inhibitor reactive center. To obtain an inhibitor that would be specific for the plasma kallikrein-kinin system enzymes, we have constructed an antitrypsin mutant having Arg at the reactive center P, residue (position 358) and Ala at residue P2 (position 357). These modifications were made because C! inhibitor, the major natural inhibitor of kallikrein and Factor XIIa, contains Arg at Pi and Ala at P2. In vitro, the novel inhibitor, a1-antitrypsin Ala357 Arg358, was more efficient than C! inhibitor for inhibiting kallikrein. Furthermore, Wistar rats pretreated with a1-antitrypsin AlW37 Arge were partially protected from the circulatory collapse caused by the administration of j-Factor XIIa.
Introduction
The plasma kinin-forming system comprises the serine protease zymogens Factor XII and prekallikrein and the nonenzymatic cofactor high-molecular-weight kininogen (1) . Upon activation, Factor XII is proteolytically converted into a-and 3-Factor XIIa (2) , and prekallikrein into a-and $l-kallikrein (3) . When zymogen activation takes place on a negatively charged surface, highmolecular-weight kininogen functions as a cofactor because it increases the rate of reciprocal activation of Factor XII by kallikrein and ofprekallikrein by Factor XIIa (4) . High-molecularweight kininogen also serves as a substrate for a-and fl-kallikrein and for Factor XIIa (5) (6) (7) . At an early stage of high-molecularweight kininogen proteolytic cleavage, kinins such as the nonapeptide bradykinin are released (5) (6) (7) . These peptides are potent inflammatory mediators that enhance vascular permeability and cause arterial vasodilation and venous constriction (8) .
Septic shock and angioedema attacks are associated with activation of the plasma kinin-forming system (1) . However, it is not known whether this mechanism induces the symptoms observed in these disease states or whether activation of this pathway merely represents an accompanying phenomenon. This question could be addressed by examining the influence of a specific and efficient inhibitor of Factor XIIa and kallikrein on the clinical course ofthese pathological conditions. Furthermore, ifa favorable effect is detectable, the availability ofsuch an agent would represent a significant step toward the development of new therapeutic strategies.
In normal plasma, a-and ,8-Factor XIIa as well as kallikrein are predominantly controlled by the serine protease inhibitor C1 inhibitor (9), a molecule whose existence was first recognized by Ratnoff and Lepow (10 The rats were then placed in a plastic tube for the restriction of their movements, where they were left to recover from anesthesia. Arterial pressure and heart rate were monitored using a pressure transducer (Statham, Hato Rey, PR) connected to an electrogalvanometer (Philips 2000, Eindhoven, Netherlands), and recorded on a light-sensitive oscillograph (Mannarp 150, Electronic Institute, London, UK). The study was initiated 90-120 min after the end of anesthesia, when blood pressure and heart rate were stable and normal. Over a period of 5 min, the animals were pretreated by a continuous intravenous perfusion of the agent under investigation. 5 min after the end of the pretreatment period, a bolus intravenous injection of (3-Factor XIIa (1.0 Mg) was administered. Blood pressure and heart rate were continuously recorded during 15 min, from the start ofthe pretreatment injection (Fig. 1 , time = 0) until 5 min after the bolus administration of (3-Factor XIIa (Fig. 1 , time = 15 min). Blood pressure changes were expressed as means±SD, and groups were compared using one-way analysis of variance and Student's t tests.
Results
Interaction ofbloodproteolytic enzymes with a,-antitrypsin mu- (Table I) . However, a1-antitrypsin Ala357 Arg358 was less efficient than a1-antitrypsin Arg358 for the inactivation of 3-Factor XIIa (3.8 times) as well as of thrombin (4.9 times) ( Table I ).
Anticoagulant effect ofal-antitrypsin mutants. Anesthetized male Wistar rats weighing 232-271 g received an intravenous bolus of a1-antitrypsin Arg358 or a,-antitrypsin Ala357 Arg358. 5 min later, the anticoagulant effect of these treatments was assessed using the thrombin time. Control values were obtained by studying animals treated with a1-antitrypsin Val358, an oxidation-resistant variant that possesses the same inhibitory spectrum as a1-antitrypsin Met358 and therefore does not exhibit antitoagulant activity (16) . Two animals treated with 0.7 mg of a1-antitrypsin Arg358 had a prolonged thrombin time, respectively by a factor of 2.3 and 1.4, whereas a 1.1-fold prolongation was detectable in the animal that received half this dose (Table II) .
In contrast, rats treated with 0.7 mg of al-antitrypsin Ala357 (Table II) .
Effect of a,-antitrypsin mutants on (-Factor XIIa-induced arterial hypotension. Conscious normotensive male Wistar rats weighing 241-268 g were pretreated intravenously during 5 min with either saline (Fig. 1 A) , 0.7 mg of al-antitrypsin Val358 (Fig.  1 B) , or 0.7 mg of a I-antitrypsin Ala357 Arg358 (Fig. 1 C) . 5 min after the end of pretreatment, the animals received an intravenous bolus of 1.0 ,ug of (-Factor XIIa (Fig. 1, vertical arrows) . Nearly identical peak arterial blood pressure reductions were recorded in rats pretreated with saline (-26±1 mmHg, n = 4; Fig. 1 A) or a1-antitrypsin Val358 (-27±2 mmHg, n = 4; Fig. 1  B) , whereas significantly smaller blood pressure decreases were observed in animals pretreated with aI-antitrypsin Ala357 Arg358
(-14±3 mmHg, n = 4, P < 0.01; Fig. 1 C) .
Discussion aI-Antitrypsin Ala357 Arg358 differs from a1-antitrypsin Arg358 in possessing Ala instead of Pro at position P2 of the reactive center. This additional mutation modifies the relative inhibition ofkallikrein and thrombin (Table I) . a,-Antitrypsin Ala357 Ag358 is a better inhibitor of kallikrein than of thrombin (4.9-fold), in contrast to a1-antitrypsin Arg358, which is more efficient against thrombin than against kallikrein (5. , it was proposed that the mechanism responsible for the hypotensive reaction included prekallikrein activation by (3-Factor XIIa, followed by high-molecular-weight kininogen cleavage by kallikrein leading to the release of bradykinin. Subsequent studies showed that arterial hypotension is also observed when purified and catalytically active (3-Factor XIIa is employed instead ofplasma protein fraction (25, 26) . In these experiments, the hypotensive response is me- (27) . A similar observation is now made in animals pretreated with a1-antitrypsin Ala357 Arg358 (Fig. 1 C) , thereby demonstrating that the double mutant can prevent a well documented kinin-mediated reaction. The effect of ai-antitrypsin Ala357 Arg358 is related to its specific and efficient inactivation ofthe proteolytic enzymes ofthe kallikrein-kinin system. Indeed, a1-antitrypsin Val358, which is active against neutrophil elastase but not against XIIa or kallikrein (18), did not prevent the hypotensive response to (3-Factor XIIa (Fig.  1 B) . Furthermore, because a1-antitrypsin Ala37 Arg358 prevents the kinin-dependent consequences of prekallikrein and Factor XII activation, it is likely that this inhibitor will also inhibit the kinin-independent manifestations that are observed when these enzymes are activated. These reactions include activation of the blood coagulation and fibrinolytic pathways and ofblood neutrophils (1).
In vivo manifestation ofthe specificity ofa,-antitrypsin Ala357 Ag358 and further indication ofits clinical potential was obtained by studying the anticoagulant properties of the double mutant.
With a dose of 0.7 mg of a1-antitrypsin Ala357 Arg358, which reduced the hypotensive reaction to (3-Factor XIIa (Fig. 1 C) , no prolongation of the thrombin time was detectable, whereas with the same dose of a,-antitrypsin Arg358, the thrombin time was prolonged significantly (Table II) . Therefore, in vivo, a,-antitrypsin Ala357 Arg358 can efficiently inhibit the enzymes of the plasma kinin-forming system without causing increased inhibition ofthrombin, an observation that confirms and amplifies the results obtained by our kinetic studies in purified systems.
Further studies are now required to establish the inhibitory activity of a1-antitrypsin Ala357 Arg358 toward other Arg-specific proteases of the coagulation, complement, and fibrinolytic systems. These studies will determine whether aI-antitrypsin Ala357
Arg358 is sufficiently specific for the enzymes ofthe plasma kininforming system or whether additional mutants should be constructed. If new molecules must be created, the detailed sequence informations now available for most plasma protease inhibitors ofthe serpin superfamily should permit the generation of a new set of molecules with the desired specificity.
